. 2016 Jul 26;6:30252. doi: 10.1038/srep30252

Table 1. Protective effect of BSE and SFN on diabetes-induced cardiac dysfunction.

	WT	WT-BSE-low	WT-BSE-high	WT-SFN	db/db	db/db -BSE-low	db/db -BSE-high	db/db -SFN
IVS; d (mm)	0.63 ± 0.00	0.62 ± 0.02	0.62 ± 0.02	0.63 ± 0.03	0.63 ± 0.03	0.62 ± 0.02	0.61 ± 0.02	0.63 ± 0.04
LVID; d (mm)	3.74 ± 0.02	3.74 ± 0.06	3.76 ± 0.01	3.79 ± 0.02	4.09 ± 0.08^*	4.12 ± 0.07^*	4.05 ± 0.06^*	4.06 ± 0.05^*
LVPW; d (mm)	0.85 ± 0.05	0.82 ± 0.05	0.80 ± 0.04	0.85 ± 0.06	0.84 ± 0.03	0.82 ± 0.04	0.78 ± 0.03	0.79 ± 0.04
IVS; s (mm)	1.01 ± 0.03	0.99 ± 0.02	0.96 ± 0.07	1.00 ± 0.02	1.00 ± 0.02	1.00 ± 0.02	0.98 ± 0.02	0.99 ± 0.03
LVID; s (mm)	2.06 ± 0.05	2.04 ± 0.03	2.07 ± 0.06	2.09 ± 0.03	2.83 ± 0.08^*	2.65 ± 0.07*,#	2.50 ± 0.05*,#	2.48 ± 0.04*,#
LVPW; s (mm)	1.29 ± 0.02	1.30 ± 0.01	1.28 ± 0.02	1.28 ± 0.03	1.30 ± 0.02	1.28 ± 0.02	1.27 ± 0.02	1.30 ± 0.04
LV Vol; d (mm)	59.52 ± 0.60	59.54 ± 2.18	60.22 ± 0.61	61.62 ± 0.61	73.93 ± 2.59^*	74.89 ± 2.45^*	71.98 ± 2.40^*	72.56 ± 2.17^*
LV Vol; s (mm)	13.72 ± 0.71	13.42 ± 0.53	13.88 ± 0.98	14.19 ± 0.54	31.43 ± 0.74^*	25.72 ± 1.81*,#	22.37 ± 1.00*,#	21.97 ± 0.89*,#
%EF	76.94 ± 1.16	77.44 ± 1.35	76.94 ± 1.70	76.98 ± 0.65	57.93 ± 1.32^*	65.67 ± 2.21*,#	68.88 ± 1.94*,#	69.72 ± 0.78*,#
%FS	44.88 ± 1.10	45.36 ± 1.33	44.90 ± 1.60	44.95 ± 0.61	30.18 ± 0.92^*	35.72 ± 1.66*,#	38.16 ± 1.59*,#	38.84 ± 0.64*,#
LV Mass (mg)	94.31 ± 4.69	88.55 ± 1.29	90.37 ± 4.10	92.42 ± 6.81	109.27 ± 4.86^*	106.74 ± 5.08^*	101.33 ± 0.96*,#	101.10 ± 3.95*,#

Notes: IVS: interventricular septum; LVID; d: left ventricular internal diastolic diameter; LVID; s: left ventricular internal systolic diameter; LVPW: left ventricular posterior wall; EF: ejection fraction; FS: fractional shortening; LV vol; s: left ventricular end systolic volume; LV vol; d: left ventricular end diastolic volume; LV mass: left ventricular mass. Data are presented as means ± SD. *p < 0.05 vs. WT group; ^#p < 0.05 vs. db/db group.